Author

Sean Gardiner 1

1 Pfizer Inc,New York, NY,United States

ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Marla C. Dubinsky, Geert R. D'Haens, William J. Sandborn, Julian Panés, Chinyu Su, Nervin Lawendy, Irina Lazariciu, Sean Gardiner, Rajiv Mundayat, nicole kulisek, Irene Modesto, Siew C. Ng, Joana Torres

IMPACT OF PRIOR TUMOUR NECROSIS FACTOR INHIBITOR FAILURE AND PRIOR CORTICOSTEROID USE ON THE MAINTENANCE OF EFFICACY OF TOFACITINIB FOLLOWING DOSE REDUCTION IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Marla C. Dubinsky, William J. Sandborn, Sean Gardiner, Rajiv Mundayat, Irene Modesto, Jerome Paulissen, Severine Vermeire, Paulo Kotze, Chinyu Su, Nervin Lawendy, nicole kulisek, Geert D’Haens, Joana Torres

MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: FINAL RESULTS OF A SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY, OCTAVE OPEN

Walter Reinisch, Jean-Frédéric Colombel, Mark T. Osterman, Patricio Ibáñez, Severine Vermeire, Peter Irving, Susan B. Connelly, Rajiv Mundayat, Nervin Lawendy, Sean Gardiner, Chinyu Su

NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Geert R. D'Haens, Genoile O. Santana, William J. Sandborn, Irene Modesto, Chinyu Su, Nervin Lawendy, Jerome Paulissen, Marla C. Dubinsky, Miguel Regueiro, nicole kulisek, Sean Gardiner, Rajiv Mundayat, Joana Torres

TREATMENT OUTCOME OF TOFACITINIB DOSE REDUCTION TO 5 MG BID VS REMAINING ON 10 MG BID IN PATIENTS WITH UC WHO WERE IN STABLE REMISSION ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Severine Vermeire, Chinyu Su, Nervin Lawendy, Taku Kobayashi, William Sandborn, David T. Rubin, Irene Modesto, Sean Gardiner, nicole kulisek, Haiying Zhang, Wenjin Wang, Julian Panés

Item 1 - 5 / 5
1